Biotherapies in large vessel vasculitis

被引：50

作者：

Ferfar, Y. ^{[1
]}

Mirault, T. ^{[2
]}

Desbois, A. C. ^{[1
]}

Comarmond, C. ^{[1
]}

Messas, E. ^{[2
]}

Savey, L. ^{[1
]}

Domont, F. ^{[1
]}

Cacoub, P. ^{[1
]}

Saadoun, D. ^{[1
]}

机构：

[1] Univ Paris 06, Grp Hosp Pitie Salpetriere, AP HP,Serv Med Interne & Immunol Clin,DHU I2B, Ctr Reference Malad Autoimmunes & Syst Rares,Immu, Paris, France

[2] Grp Hosp HEGP, AP HP, Serv Med Vasc, Ctr Natl Reference Malad Vasc Rares, Paris, France

来源：

AUTOIMMUNITY REVIEWS | 2016年 / 15卷 / 06期

关键词：

Giant cell arteritis; Takayasu; Behcet's disease; Relapsing polychondritis; Biotherapy; GIANT-CELL ARTERITIS; REFRACTORY TAKAYASU ARTERITIS; PLACEBO-CONTROLLED TRIAL; NECROSIS FACTOR THERAPY; ANTI-TNF-ALPHA; RELAPSING POLYCHONDRITIS; BEHCETS-DISEASE; POLYMYALGIA-RHEUMATICA; EULAR RECOMMENDATIONS; SUSTAINED RESPONSE;

D O I：

10.1016/j.autrev.2016.02.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are large vessel vasculitis (LW) and aortic involvement is not uncommon in Behcet's disease (BD) and relapsing polychondritis (RP). Glucocorticosteroids are the mainstay of therapy in LW. However, a significant proportion of patients have glucocorticoid dependance, serious side effects or refractory disease to steroids and other immunosuppressive treatments such as cyclophosphamide, azathioprine, mycophenolate mofetil and methotrexate. Recent advances in the understanding of the pathogenesis have resulted in the use of biological agents in patients with LW. Anti-tumor necrosis factor-alpha drugs seem effective in patients with refractory Takayasu arteritis and vascular BD but have failed to do so in giant cell arteritis. Preliminary reports on the use of the anti-IL6-receptor antibody (tocilizumab), in LW have been encouraging. The development of new biologic targeted therapies will probably open a promising future for patients with LW. (C) 2016 Elsevier B.V. All rights reserved.

引用

页码：544 / 551

页数：8

共 50 条

[21] Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy
Yoshifuji, Hajime
MODERN RHEUMATOLOGY, 2019, 29 (02) : 287 - 293
[22] Large vessel vasculitis
Maksimowicz-McKinnon, K.
Hoffman, G. S.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (01) : S58 - S59
[23] Large vessel vasculitis
Zavadilova, Lucie
Gergely, Ladislav
COR ET VASA, 2018, 60 (03) : E251 - E262
[24] Large vessel vasculitis
S. Weigand
M. Fleck
Zeitschrift für Rheumatologie, 2014, 73 (5) : 447 - 457
[25] Emerging therapies in large vessel vasculitis
Banerjee, Siwalik
Stapleton, Philip P.
Dasgupta, Bhaskar
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (08) : 741 - 746
[26] Imaging in large-vessel vasculitis
Schmidt, Wolfgang A.
Nielsen, Berit D.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2020, 34 (06):
[27] Advances in the Diagnosis of Large Vessel Vasculitis
Espigol-Frigole, Georgina
Prieto-Gonzalez, Sergio
Alba, Marco A.
Tavera-Bahillo, Itziar
Garcia-Martinez, Ana
Gilabert, Rosa
Hernandez-Rodriguez, Jose
Cid, Maria C.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (01) : 125 - 140
[28] News on the imaging of large vessel vasculitis
Schaefer, Valentin S.
Petzinna, Simon M.
Schmidt, Wolfgang A.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024, : 800 - 811
[29] Large vessel vasculitis
Czihal, Michael
Hoffmann, Ulrich
NEPHROLOGE, 2021, 16 (06): : 350 - 359
[30] Biologic treatment of large-vessel vasculitides
Schaefer, Valentin S.
Zwerina, Jochen
CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (01) : 31 - 37

← 1 2 3 4 5 →